There are many reasons to be excited by the science being presented at this year’s American Society for Clinical Oncology meeting. The data...
Via Krishan Maggon
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Your new post is loading...
Your new post is loading...
No comment yet.
Sign up to comment
Krishan Maggon 's curator insight,
March 9, 2015 6:20 AM
Highlights
• Immune checkpoint blockade inhibitors are revolutionizing the care for patients with cancer. • Specifically, anti-PD-1 and anti-PD-L1 agents have demonstrated marked clinical success in a wide range of malignancies by providing durable benefits with minimal toxicities. • Herein, we review the pre-clinical and clinical activity of these agents in multiple malignancies. • In addition, we review areas that need further development in order to improve the clinical efficacy of these agents.
doi:10.1016/j.molimm.2015.02.009 Molecular Immunology Available online 5 March 2015 In Press, Corrected Proof — Note to users Review Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy ☆Abhisek Swaika, William A. Hammond, Richard W. Joseph, |
Krishan Maggon 's curator insight,
March 21, 2015 1:50 AM
Macrophages are critical effectors of antibody therapies for cancer View full textDownload full textOpen accessDOI:10.1080/19420862.2015.1011450Kipp Weiskopfabc* & Irving L Weissmanabcd
pages 303-310 Publishing models and article dates explainedReceived: 4 Jan 2015Accepted: 15 Jan 2015Accepted author version posted online: 10 Feb 2015Article Views: 321
Krishan Maggon 's curator insight,
March 21, 2015 1:53 AM
Macrophages are critical effectors of antibody therapies for cancer View full textDownload full textOpen accessDOI:10.1080/19420862.2015.1011450Kipp Weiskopfabc* & Irving L Weissmanabcd
pages 303-310 Publishing models and article dates explainedReceived: 4 Jan 2015Accepted: 15 Jan 2015Accepted author version posted online: 10 Feb 2015Article Views: 321
Krishan Maggon 's curator insight,
January 9, 2015 10:19 AM
MOLECULAR THERAPY — ONCOLYTICS | REVIEW ARTICLE OPEN Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancerDmitriy Zamarin & Jedd D WolchokAffiliationsCorresponding authorMolecular Therapy — Oncolytics 1, Article number: 14004 (2014) doi:10.1038/mto.2014.4Received 30 June 2014 Accepted 30 June 2014 Published online 10 December 2014 |